Logo image of FLDM

FLUIDIGM CORP (FLDM) Stock Fundamental Analysis

NASDAQ:FLDM - Nasdaq - Common Stock

3.71  -0.28 (-7.02%)

After market: 4.02 +0.31 (+8.36%)

Fundamental Rating

1

Taking everything into account, FLDM scores 1 out of 10 in our fundamental rating. FLDM was compared to 55 industry peers in the Life Sciences Tools & Services industry. FLDM has a bad profitability rating. Also its financial health evaluation is rather negative. FLDM does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year FLDM has reported negative net income.
FLDM Yearly Net Income VS EBIT VS OCF VS FCFFLDM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 -20M -40M -60M

1.2 Ratios

Industry RankSector Rank
ROA -21.52%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
FLDM Yearly ROA, ROE, ROICFLDM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 -50 -100 -150

1.3 Margins

Industry RankSector Rank
OM -51.66%
PM (TTM) -45.36%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FLDM Yearly Profit, Operating, Gross MarginsFLDM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 0 20 -20 40 -40 60 -60

More info and screens

1

2. Health

2.1 Basic Checks

The number of shares outstanding for FLDM has been increased compared to 1 year ago.
Compared to 1 year ago, FLDM has a worse debt to assets ratio.
FLDM Yearly Shares OutstandingFLDM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M
FLDM Yearly Total Debt VS Total AssetsFLDM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 100M 200M 300M

2.2 Solvency

FLDM has an Altman-Z score of -2.94. This is a bad value and indicates that FLDM is not financially healthy and even has some risk of bankruptcy.
A Debt/Equity ratio of 0.68 indicates that FLDM is somewhat dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.68
Debt/FCF N/A
Altman-Z -2.94
ROIC/WACCN/A
WACCN/A
FLDM Yearly LT Debt VS Equity VS FCFFLDM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 1.45 indicates that FLDM should not have too much problems paying its short term obligations.
FLDM has a Quick Ratio of 1.03. This is a normal value and indicates that FLDM is financially healthy and should not expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 1.45
Quick Ratio 1.03
FLDM Yearly Current Assets VS Current LiabilitesFLDM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 50M 100M

More info and screens

2

3. Growth

3.1 Past

The earnings per share for FLDM have decreased by -6.85% in the last year.
FLDM shows a decrease in Revenue. In the last year, the revenue decreased by -5.48%.
The Revenue has been growing slightly by 4.58% on average over the past years.
EPS 1Y (TTM)-6.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)-5.48%
Revenue growth 3Y4.94%
Revenue growth 5Y4.58%
Sales Q2Q%-14.22%

3.2 Future

Based on estimates for the next years, FLDM will show a decrease in Earnings Per Share. The EPS will decrease by -4.60% on average per year.
The Revenue is expected to grow by 4.08% on average over the next years.
EPS Next Y-30.77%
EPS Next 2Y-17.18%
EPS Next 3Y-8.28%
EPS Next 5Y-4.6%
Revenue Next Year-0.48%
Revenue Next 2Y4.54%
Revenue Next 3Y3.89%
Revenue Next 5Y4.08%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
FLDM Yearly Revenue VS EstimatesFLDM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M
FLDM Yearly EPS VS EstimatesFLDM Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -0.5 -1 -1.5 -2 -2.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for FLDM. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for FLDM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FLDM Price Earnings VS Forward Price EarningsFLDM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -6.32
FLDM Per share dataFLDM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 1.5

4.3 Compensation for Growth

A cheap valuation may be justified as FLDM's earnings are expected to decrease with -8.28% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-17.18%
EPS Next 3Y-8.28%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for FLDM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FLUIDIGM CORP

NASDAQ:FLDM (4/5/2022, 8:24:22 PM)

After market: 4.02 +0.31 (+8.36%)

3.71

-0.28 (-7.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-17 2022-02-17/amc
Earnings (Next)05-05 2022-05-05/amc
Inst Owners365.92%
Inst Owner Change2.06%
Ins Owners0.95%
Ins Owner Change0%
Market Cap285.37M
Analysts85.71
Price Target6.12 (64.96%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.19
P/FCF N/A
P/OCF N/A
P/B 3.02
P/tB N/A
EV/EBITDA -6.32
EPS(TTM)-0.78
EYN/A
EPS(NY)-1.02
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS1.7
BVpS1.23
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -21.52%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -51.66%
PM (TTM) -45.36%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 0.68
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.45
Quick Ratio 1.03
Altman-Z -2.94
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y-30.77%
EPS Next 2Y-17.18%
EPS Next 3Y-8.28%
EPS Next 5Y-4.6%
Revenue 1Y (TTM)-5.48%
Revenue growth 3Y4.94%
Revenue growth 5Y4.58%
Sales Q2Q%-14.22%
Revenue Next Year-0.48%
Revenue Next 2Y4.54%
Revenue Next 3Y3.89%
Revenue Next 5Y4.08%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A